| NCT07086222 | Efficacy and Safety of NVX-CoV2705 | NOT_YET_RECRUITING | PHASE4 | 2025-11-10 | 2026-07-09 | 2026-01-09 |
| NCT07079670 | Safety and Immunogenicity of NVX-CoV2705 | NOT_YET_RECRUITING | PHASE3 | 2025-10-16 | 2026-06-16 | 2026-04-16 |
| NCT06482359 | Lot Consistency Study of COVID-19 and Influenza Combination Vaccine | WITHDRAWN | PHASE2, PHASE3 | 2025-02-01 | 2026-05-17 | 2025-11-16 |
| NCT06291857 | A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-12-09 | 2026-09-30 | 2026-07-26 |
| NCT06485752 | Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine | WITHDRAWN | PHASE2, PHASE3 | 2024-11 | 2025-02-04 | 2025-02-04 |
| NCT06409663 | A Strain Change Study for SARS-CoV-2 rS Vaccines | COMPLETED | PHASE3 | 2024-10-14 | 2025-04-17 | 2024-10-15 |
| NCT06633835 | Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States | ACTIVE_NOT_RECRUITING | PHASE4 | 2024-09-20 | 2025-08-31 | 2025-06-30 |
| NCT05925127 | Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines | COMPLETED | PHASE2, PHASE3 | 2023-10-16 | 2024-05-21 | 2024-05-21 |
| NCT05975060 | A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. | COMPLETED | PHASE2, PHASE3 | 2023-09-07 | 2024-05-20 | 2023-11-15 |
| NCT05973006 | Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines | COMPLETED | PHASE3 | 2023-08-16 | 2024-09-30 | 2024-04-01 |
| NCT05875701 | Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines | COMPLETED | PHASE3 | 2023-03-28 | 2023-11-11 | 2023-11-11 |
| NCT05519839 | A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine | COMPLETED | PHASE2 | 2022-12-30 | 2023-12-24 | 2023-07-25 |
| NCT05468736 | Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2022-07-22 | 2025-10-25 | 2024-01-16 |
| NCT05463068 | Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults | COMPLETED | PHASE3 | 2022-07-11 | 2022-09-01 | 2022-08-17 |
| NCT05372588 | Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines | COMPLETED | PHASE3 | 2022-05-25 | 2024-04-07 | 2022-07-17 |
| NCT05112848 | A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19) | COMPLETED | PHASE2 | 2022-02-28 | 2022-11-30 | 2022-05-23 |
| NCT05029856 | Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults | WITHDRAWN | PHASE1, PHASE2 | 2022-02-04 | 2022-08 | 2022-08 |
| NCT04961541 | Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine | COMPLETED | PHASE1, PHASE2 | 2021-09-08 | 2022-04-22 | 2021-12-22 |
| NCT04611802 | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | COMPLETED | PHASE3 | 2020-12-27 | 2023-12-15 | 2023-04-10 |
| NCT04583995 | A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom | COMPLETED | PHASE3 | 2020-09-28 | 2022-03-29 | 2022-03-29 |
| NCT04533399 | A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults | COMPLETED | PHASE2 | 2020-08-17 | 2022-01-19 | 2021-12-07 |
| NCT04368988 | Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant | COMPLETED | PHASE1, PHASE2 | 2020-05-25 | 2022-06-01 | 2022-06-01 |
| NCT04120194 | Phase 3 Pivotal Trial of NanoFluâ„¢ in Older Adults | COMPLETED | PHASE3 | 2019-10-14 | 2020-12-13 | 2020-10-29 |
| NCT03658629 | Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults | TERMINATED | PHASE2 | 2018-09-24 | 2019-04-26 | 2019-04-26 |
| NCT03293498 | Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu) | COMPLETED | PHASE1, PHASE2 | 2017-09-18 | 2018-10-29 | 2018-03-14 |
| NCT03026348 | Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1â„¢ Adjuvants In Clinically-Stable Older Adults | COMPLETED | PHASE2 | 2017-01 | 2018-05-18 | 2017-04 |
| NCT02624947 | A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization | COMPLETED | PHASE3 | 2015-12 | 2019-07-12 | 2018-12-28 |
| NCT02608502 | A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults | COMPLETED | PHASE3 | 2015-11 | 2016-12 | 2016-12 |
| NCT02593071 | Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year. | COMPLETED | PHASE2 | 2015-10 | 2016-11 | 2016-11 |
| NCT02370589 | Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects | COMPLETED | PHASE1 | 2015-02 | 2016-04 | 2016-04 |
| NCT02307851 | Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults | COMPLETED | PHASE2 | 2014-11 | 2015-06 | 2015-06 |
| NCT02296463 | A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age | COMPLETED | PHASE1 | 2014-11 | 2016-04 | 2015-09 |
| NCT02266628 | Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults | COMPLETED | PHASE2 | 2014-10 | 2016-03 | 2016-03 |
| NCT02247726 | RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women. | COMPLETED | PHASE2 | 2014-09 | 2016-07 | 2016-07 |
| NCT02078674 | A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1â„¢ Adjuvant | COMPLETED | PHASE1, PHASE2 | 2014-03 | 2015-07 | 2015-07 |
| NCT01960686 | RSV F Dose-Ranging Study in Women | COMPLETED | PHASE2 | 2013-10 | 2014-04 | 2014-04 |
| NCT01897701 | A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1 | COMPLETED | PHASE1 | 2013-07 | 2014-08 | 2014-08 |
| NCT01709019 | RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly | COMPLETED | PHASE1 | 2012-10 | 2014-03 | 2013-07 |
| NCT01704365 | RSV-F Vaccine Dose Ranging Study in Young Women | COMPLETED | PHASE2 | 2012-10 | 2013-05 | 2013-04 |
| NCT01596725 | A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2 | COMPLETED | PHASE1 | 2012-05 | 2013-08 | 2012-08 |
| NCT01594320 | A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1 | COMPLETED | PHASE1 | 2012-04 | 2013-08 | 2012-07 |
| NCT01561768 | A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults | COMPLETED | PHASE2 | 2012-03 | 2013-01 | 2013-01 |
| NCT01290419 | Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine | COMPLETED | PHASE1 | 2010-12 | 2011-12 | 2011-12 |
| NCT01014806 | Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults | COMPLETED | PHASE2 | 2009-11 | 2010-05 | 2010-05 |
| NCT01072799 | Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine | COMPLETED | PHASE2 | 2009-10 | 2012-03 | 2012-03 |
| NCT00903552 | Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) | COMPLETED | PHASE2 | 2009-05 | 2009-10 | 2009-10 |
| NCT00754455 | Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults | COMPLETED | PHASE2 | 2008-09 | 2009-03 | 2009-03 |
| NCT00519389 | Safety, Reactogenicity and Immunogenicity of an H5N1 VLP | COMPLETED | PHASE1, PHASE2 | 2007-07 | 2008-11 | 2008-11 |